48-4776-42
antibody from Invitrogen Antibodies
Targeting: FOXP3
AIID, DIETER, IPEX, JM2, PIDX, SCURFIN, XPID
Antibody data
- Antibody Data
- Antigen structure
- References [52]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [30]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 48-4776-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- FOXP3 Monoclonal Antibody (PCH101), eFluor™ 450, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: eBioscience offers a panel of monoclonal antibodies to different epitopes of human Foxp3, providing useful tools for investigating the complete expression pattern of Foxp3 at the protein level, and discerning the precise subsets of Foxp3^+ cells. The PCH101 antibody reacts with the amino terminus of human foxp3 protein also known as FORKHEAD BOX P3, SCURFIN, and JM2; cross reactivity of this antibody to other proteins has not been determined. Foxp3, a 49-55 kDa protein, is a member of the forkhead/winged-helix family of transcriptional regulators, and was identified as the gene defective in 'scurfy' (sf) mice. Constitutive high expression of Foxp3 mRNA has been shown in CD4+CD25+ regulatory T cells (Treg cells), and ectopic expression of foxp3 in CD4+CD25- cells imparts a Treg phenotype in these cells. Intracellular staining of human peripheral blood mononuclear cells (PBMCs) with PCH101 antibody using the anti-human Foxp3 Staining Set and protocol reveals approximately 0.5-4% of lymphocytes staining, with the majority of staining occurring in the CD25^bright population. This is subject to donor variability. PCH101 crossreacts with rhesus, chimpanzee and cynomolgus. We recommend the use of CD4 (OKT4, Product # 11-0048-42 , or RPA-T4, Product # 11-0049-42 , depending on the species) and CD25 (BC96, Product # 17-0259-42). Applications Reported: This PCH101 antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This PCH101 antibody has been pre-titrated and tested by intracellular staining and by flow cytometric analysis using the Foxp3/Transcription Factor Staining Buffer Set (
- Reactivity
- Human
- Host
- Rat
- Isotype
- IgG
- Antibody clone number
- PCH101
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung.
People critically ill with COVID-19 exhibit peripheral immune profiles predictive of mortality and reflective of SARS-CoV-2 lung viral burden.
Clusters of Tolerogenic B Cells Feature in the Dynamic Immunological Landscape of the Pregnant Uterus.
A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma.
Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis.
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer.
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues.
An Autocrine TNFα-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability In Vitro.
DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4(+)CD25(high) FOXP3(+) Regulatory T Cells but Does Not Affect Their Suppressive Capacity.
Non-conventional Inhibitory CD4(+)Foxp3(-)PD-1(hi) T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Intradermal injection of low dose human regulatory T cells inhibits skin inflammation in a humanized mouse model.
RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways.
IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Blocking the recruitment of naive CD4(+) T cells reverses immunosuppression in breast cancer.
Equilibrium of Treg/Th17 cells of peripheral blood in syphilitic patients with sero-resistance.
Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells--possible implications for the ICOS/ICOS-ligand axis in disease course and resolution.
Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.
Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.
Development of Type 2, But Not Type 1, Leprosy Reactions is Associated with a Severe Reduction of Circulating and In situ Regulatory T-Cells.
Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry.
Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants.
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39.
Human T cells upregulate CD69 after coculture with xenogeneic genetically-modified pig mesenchymal stromal cells.
T regulatory cells and related immunoregulatory factors in polymorphic light eruption following ultraviolet A1 challenge.
Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
Impaired function of regulatory T cells in cord blood of children of allergic mothers.
Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy.
Induction of endometriosis alters the peripheral and endometrial regulatory T cell population in the non-human primate.
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
A functional variant in FCRL3 is associated with higher Fc receptor-like 3 expression on T cell subsets and rheumatoid arthritis disease activity.
OMIP-006: phenotypic subset analysis of human T regulatory cells via polychromatic flow cytometry.
Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses.
Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells.
CD40 signalling induces IL-10-producing, tolerogenic dendritic cells.
Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis.
CD4(+) regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection.
Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1.
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.
IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin.
FOXP3 regulates TLR10 expression in human T regulatory cells.
Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART.
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C.
Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells.
Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells.
Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells.
Ogongo P, Tezera LB, Ardain A, Nhamoyebonde S, Ramsuran D, Singh A, Ng'oepe A, Karim F, Naidoo T, Khan K, Dullabh KJ, Fehlings M, Lee BH, Nardin A, Lindestam Arlehamn CS, Sette A, Behar SM, Steyn AJ, Madansein R, Kløverpris HN, Elkington PT, Leslie A
The Journal of clinical investigation 2021 May 17;131(10)
The Journal of clinical investigation 2021 May 17;131(10)
People critically ill with COVID-19 exhibit peripheral immune profiles predictive of mortality and reflective of SARS-CoV-2 lung viral burden.
Cillo AR, Somasundaram A, Shan F, Cardello C, Workman CJ, Kitsios GD, Ruffin AT, Kunning S, Lampenfeld C, Onkar S, Grebinoski S, Deshmukh G, Methe B, Liu C, Nambulli S, Andrews LP, Duprex WP, Joglekar AV, Benos PV, Ray P, Ray A, McVerry BJ, Zhang Y, Lee JS, Das J, Singh H, Morris A, Bruno TC, Vignali DAA
Cell reports. Medicine 2021 Dec 21;2(12):100476
Cell reports. Medicine 2021 Dec 21;2(12):100476
Clusters of Tolerogenic B Cells Feature in the Dynamic Immunological Landscape of the Pregnant Uterus.
Benner M, Feyaerts D, García CC, Inci N, López SC, Fasse E, Shadmanfar W, van der Heijden OWH, Gorris MAJ, Joosten I, Ferwerda G, van der Molen RG
Cell reports 2020 Sep 29;32(13):108204
Cell reports 2020 Sep 29;32(13):108204
A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma.
Harb H, Stephen-Victor E, Crestani E, Benamar M, Massoud A, Cui Y, Charbonnier LM, Arbag S, Baris S, Cunnigham A, Leyva-Castillo JM, Geha RS, Mousavi AJ, Guennewig B, Schmitz-Abe K, Sioutas C, Phipatanakul W, Chatila TA
Nature immunology 2020 Nov;21(11):1359-1370
Nature immunology 2020 Nov;21(11):1359-1370
Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis.
Henderson LA, Hoyt KJ, Lee PY, Rao DA, Jonsson AH, Nguyen JP, Rutherford K, Julé AM, Charbonnier LM, Case S, Chang MH, Cohen EM, Dedeoglu F, Fuhlbrigge RC, Halyabar O, Hazen MM, Janssen E, Kim S, Lo J, Lo MS, Meidan E, Son MBF, Sundel RP, Stoll ML, Nusbaum C, Lederer JA, Chatila TA, Nigrovic PA
JCI insight 2020 Mar 26;5(6)
JCI insight 2020 Mar 26;5(6)
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer.
Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA
Immunity 2020 Jan 14;52(1):183-199.e9
Immunity 2020 Jan 14;52(1):183-199.e9
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J
Scientific reports 2019 Feb 12;9(1):1853
Scientific reports 2019 Feb 12;9(1):1853
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera FG, Valerio M, Berthold D, Tawadros T, Meuwly JY, Vallet V, Baumgartner P, Thierry AC, De Bari B, Jichlinski P, Kandalaft L, Coukos G, Harari A, Bourhis J
International journal of radiation oncology, biology, physics 2019 Feb 1;103(2):320-334
International journal of radiation oncology, biology, physics 2019 Feb 1;103(2):320-334
Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues.
Lowe MM, Boothby I, Clancy S, Ahn RS, Liao W, Nguyen DN, Schumann K, Marson A, Mahuron KM, Kingsbury GA, Liu Z, Munoz Sandoval P, Rodriguez RS, Pauli ML, Taravati K, Arron ST, Neuhaus IM, Harris HW, Kim EA, Shin US, Krummel MF, Daud A, Scharschmidt TC, Rosenblum MD
JCI insight 2019 Dec 19;4(24)
JCI insight 2019 Dec 19;4(24)
An Autocrine TNFα-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability In Vitro.
Urbano PCM, Koenen HJPM, Joosten I, He X
Frontiers in immunology 2018;9:573
Frontiers in immunology 2018;9:573
DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4(+)CD25(high) FOXP3(+) Regulatory T Cells but Does Not Affect Their Suppressive Capacity.
Landman S, Cruijsen M, Urbano PCM, Huls G, van Erp PEJ, van Rijssen E, Joosten I, Koenen HJPM
Journal of immunology research 2018;2018:4973964
Journal of immunology research 2018;2018:4973964
Non-conventional Inhibitory CD4(+)Foxp3(-)PD-1(hi) T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD
Cancer cell 2018 Jun 11;33(6):1017-1032.e7
Cancer cell 2018 Jun 11;33(6):1017-1032.e7
Intradermal injection of low dose human regulatory T cells inhibits skin inflammation in a humanized mouse model.
Landman S, de Oliveira VL, van Erp PEJ, Fasse E, Bauland SCG, Joosten I, Koenen HJPM
Scientific reports 2018 Jul 3;8(1):10044
Scientific reports 2018 Jul 3;8(1):10044
RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways.
Ahn R, Yan D, Chang HW, Lee K, Bhattarai S, Huang ZM, Nakamura M, Singh R, Afifi L, Taravati K, Munoz-Sandoval P, Pauli M, Rosenblum MD, Liao W
Scientific reports 2018 Jul 27;8(1):11368
Scientific reports 2018 Jul 27;8(1):11368
IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells.
Hsieh WC, Hsu TS, Chang YJ, Lai MZ
Nature communications 2018 Jan 31;9(1):463
Nature communications 2018 Jan 31;9(1):463
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B, TRACERx Melanoma, TRACERx Renal, TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA
Cancer cell 2018 Apr 9;33(4):649-663.e4
Cancer cell 2018 Apr 9;33(4):649-663.e4
HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN
Oncotarget 2017 Dec 26;8(69):114156-114172
Oncotarget 2017 Dec 26;8(69):114156-114172
Blocking the recruitment of naive CD4(+) T cells reverses immunosuppression in breast cancer.
Su S, Liao J, Liu J, Huang D, He C, Chen F, Yang L, Wu W, Chen J, Lin L, Zeng Y, Ouyang N, Cui X, Yao H, Su F, Huang JD, Lieberman J, Liu Q, Song E
Cell research 2017 Apr;27(4):461-482
Cell research 2017 Apr;27(4):461-482
Equilibrium of Treg/Th17 cells of peripheral blood in syphilitic patients with sero-resistance.
Zhao J, Ma J, Zhang X, Li Q, Yang X
Experimental and therapeutic medicine 2016 Jun;11(6):2300-2304
Experimental and therapeutic medicine 2016 Jun;11(6):2300-2304
Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells--possible implications for the ICOS/ICOS-ligand axis in disease course and resolution.
Sakthivel P, Grunewald J, Eklund A, Bruder D, Wahlström J
Clinical and experimental immunology 2016 Feb;183(2):294-306
Clinical and experimental immunology 2016 Feb;183(2):294-306
Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.
Younis RH, Han KL, Webb TJ
Journal of immunology (Baltimore, Md. : 1950) 2016 Feb 1;196(3):1419-29
Journal of immunology (Baltimore, Md. : 1950) 2016 Feb 1;196(3):1419-29
Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.
Clever D, Roychoudhuri R, Constantinides MG, Askenase MH, Sukumar M, Klebanoff CA, Eil RL, Hickman HD, Yu Z, Pan JH, Palmer DC, Phan AT, Goulding J, Gattinoni L, Goldrath AW, Belkaid Y, Restifo NP
Cell 2016 Aug 25;166(5):1117-1131.e14
Cell 2016 Aug 25;166(5):1117-1131.e14
Development of Type 2, But Not Type 1, Leprosy Reactions is Associated with a Severe Reduction of Circulating and In situ Regulatory T-Cells.
Vieira AP, Trindade MÂ, Pagliari C, Avancini J, Sakai-Valente NY, Duarte AJ, Benard G
The American journal of tropical medicine and hygiene 2016 Apr;94(4):721-7
The American journal of tropical medicine and hygiene 2016 Apr;94(4):721-7
Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry.
Mason GM, Lowe K, Melchiotti R, Ellis R, de Rinaldis E, Peakman M, Heck S, Lombardi G, Tree TI
Journal of immunology (Baltimore, Md. : 1950) 2015 Sep 1;195(5):2030-7
Journal of immunology (Baltimore, Md. : 1950) 2015 Sep 1;195(5):2030-7
Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants.
De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C, Romano A, De Simone S, Procaccini C, La Rocca C, Carrieri PB, Maniscalco GT, Salvetti M, Buscarinu MC, Franzese A, Mozzillo E, La Cava A, Matarese G
Nature immunology 2015 Nov;16(11):1174-84
Nature immunology 2015 Nov;16(11):1174-84
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E, Gil GL, Benito AC, González-Billalabeitia E, Conesa MA, García García T, García-Garre E, Vicente V, Ayala de la Peña F
Breast cancer research : BCR 2014 Nov 29;16(6):488
Breast cancer research : BCR 2014 Nov 29;16(6):488
Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39.
Melchiotti R, Puan KJ, Andiappan AK, Poh TY, Starke M, Zhuang L, Petsch K, Lai TS, Chew FT, Larbi A, Wang de Y, Poidinger M, Rotzschke O
BMC medical genetics 2014 Jun 27;15:73
BMC medical genetics 2014 Jun 27;15:73
Human T cells upregulate CD69 after coculture with xenogeneic genetically-modified pig mesenchymal stromal cells.
Li J, Andreyev O, Chen M, Marco M, Iwase H, Long C, Ayares D, Shen Z, Cooper DK, Ezzelarab MB
Cellular immunology 2013 Sep-Oct;285(1-2):23-30
Cellular immunology 2013 Sep-Oct;285(1-2):23-30
T regulatory cells and related immunoregulatory factors in polymorphic light eruption following ultraviolet A1 challenge.
Gambichler T, Terras S, Kampilafkos P, Kreuter A, Skrygan M
The British journal of dermatology 2013 Dec;169(6):1288-94
The British journal of dermatology 2013 Dec;169(6):1288-94
Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, Brantly M, Calcedo R, Somanathan S, Richman LP, Vonderheide RH, Hulme MA, Brusko TM, Wilson JM, Flotte TR
The Journal of clinical investigation 2013 Dec;123(12):5310-8
The Journal of clinical investigation 2013 Dec;123(12):5310-8
Impaired function of regulatory T cells in cord blood of children of allergic mothers.
Hrdý J, Kocourková I, Prokešová L
Clinical and experimental immunology 2012 Oct;170(1):10-7
Clinical and experimental immunology 2012 Oct;170(1):10-7
Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy.
Palermo ML, Pagliari C, Trindade MA, Yamashitafuji TM, Duarte AJ, Cacere CR, Benard G
The American journal of tropical medicine and hygiene 2012 May;86(5):878-83
The American journal of tropical medicine and hygiene 2012 May;86(5):878-83
Induction of endometriosis alters the peripheral and endometrial regulatory T cell population in the non-human primate.
Braundmeier A, Jackson K, Hastings J, Koehler J, Nowak R, Fazleabas A
Human reproduction (Oxford, England) 2012 Jun;27(6):1712-22
Human reproduction (Oxford, England) 2012 Jun;27(6):1712-22
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB 2nd, Molhoek KR, Deacon DH, Patterson JW, Slingluff CL Jr
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012 Jan;35(1):78-88
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012 Jan;35(1):78-88
A functional variant in FCRL3 is associated with higher Fc receptor-like 3 expression on T cell subsets and rheumatoid arthritis disease activity.
Bajpai UD, Swainson LA, Mold JE, Graf JD, Imboden JB, McCune JM
Arthritis and rheumatism 2012 Aug;64(8):2451-9
Arthritis and rheumatism 2012 Aug;64(8):2451-9
OMIP-006: phenotypic subset analysis of human T regulatory cells via polychromatic flow cytometry.
Murdoch DM, Staats JS, Weinhold KJ
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2012 Apr;81(4):281-3
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2012 Apr;81(4):281-3
Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses.
Dasgupta G, Chentoufi AA, You S, Falatoonzadeh P, Urbano LA, Akhtarmalik A, Nguyen K, Ablabutyan L, Nesburn AB, BenMohamed L
Investigative ophthalmology & visual science 2011 May 17;52(6):3321-33
Investigative ophthalmology & visual science 2011 May 17;52(6):3321-33
Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells.
Gregson AL, Hoji A, Palchevskiy V, Hu S, Weigt SS, Liao E, Derhovanessian A, Saggar R, Song S, Elashoff R, Yang OO, Belperio JA
PloS one 2010 Jun 29;5(6):e11354
PloS one 2010 Jun 29;5(6):e11354
CD40 signalling induces IL-10-producing, tolerogenic dendritic cells.
Tuettenberg A, Fondel S, Steinbrink K, Enk AH, Jonuleit H
Experimental dermatology 2010 Jan;19(1):44-53
Experimental dermatology 2010 Jan;19(1):44-53
Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis.
Smolders J, Peelen E, Thewissen M, Cohen Tervaert JW, Menheere P, Hupperts R, Damoiseaux J
PloS one 2010 Dec 13;5(12):e15235
PloS one 2010 Dec 13;5(12):e15235
CD4(+) regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection.
Green AM, Mattila JT, Bigbee CL, Bongers KS, Lin PL, Flynn JL
The Journal of infectious diseases 2010 Aug 15;202(4):533-41
The Journal of infectious diseases 2010 Aug 15;202(4):533-41
Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1.
Swainson LA, Mold JE, Bajpai UD, McCune JM
Journal of immunology (Baltimore, Md. : 1950) 2010 Apr 1;184(7):3639-47
Journal of immunology (Baltimore, Md. : 1950) 2010 Apr 1;184(7):3639-47
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.
Nagata S, Ise T, Pastan I
Journal of immunology (Baltimore, Md. : 1950) 2009 Jun 15;182(12):7518-26
Journal of immunology (Baltimore, Md. : 1950) 2009 Jun 15;182(12):7518-26
IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin.
Clark RA, Kupper TS
Blood 2007 Jan 1;109(1):194-202
Blood 2007 Jan 1;109(1):194-202
FOXP3 regulates TLR10 expression in human T regulatory cells.
Bell MP, Svingen PA, Rahman MK, Xiong Y, Faubion WA Jr
Journal of immunology (Baltimore, Md. : 1950) 2007 Aug 1;179(3):1893-900
Journal of immunology (Baltimore, Md. : 1950) 2007 Aug 1;179(3):1893-900
Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART.
Epple HJ, Loddenkemper C, Kunkel D, Tröger H, Maul J, Moos V, Berg E, Ullrich R, Schulzke JD, Stein H, Duchmann R, Zeitz M, Schneider T
Blood 2006 Nov 1;108(9):3072-8
Blood 2006 Nov 1;108(9):3072-8
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
Ahmadzadeh M, Rosenberg SA
Blood 2006 Mar 15;107(6):2409-14
Blood 2006 Mar 15;107(6):2409-14
Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C.
Manigold T, Shin EC, Mizukoshi E, Mihalik K, Murthy KK, Rice CM, Piccirillo CA, Rehermann B
Blood 2006 Jun 1;107(11):4424-32
Blood 2006 Jun 1;107(11):4424-32
Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, Herr W
Bone marrow transplantation 2006 Feb;37(3):297-305
Bone marrow transplantation 2006 Feb;37(3):297-305
Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells.
Lim HW, Hillsamer P, Banham AH, Kim CH
Journal of immunology (Baltimore, Md. : 1950) 2005 Oct 1;175(7):4180-3
Journal of immunology (Baltimore, Md. : 1950) 2005 Oct 1;175(7):4180-3
Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells.
Lim HW, Hillsamer P, Banham AH, Kim CH
Journal of immunology (Baltimore, Md. : 1950) 2005 Oct 1;175(7):4180-3
Journal of immunology (Baltimore, Md. : 1950) 2005 Oct 1;175(7):4180-3
Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells.
Crellin NK, Garcia RV, Hadisfar O, Allan SE, Steiner TS, Levings MK
Journal of immunology (Baltimore, Md. : 1950) 2005 Dec 15;175(12):8051-9
Journal of immunology (Baltimore, Md. : 1950) 2005 Dec 15;175(12):8051-9
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Surface staining of normal human peripheral blood cells with Anti-Human CD4 PE (Product # 12-0049-42) (left) or Anti-Human CD25 APC (Product # 17-0259-42) (right) followed by fixation and permeabilization with the Foxp3/Transcription Factor Staining Buffer Set (Product # 00-5523-00) and intracellular staining with Anti-Human Foxp3 eFluor® 450. Cells in the lymphocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1. Flow cytometric mapping of the CD4 + CD25 + Foxp3 + cells in peripheral blood withdrawn from the syphilitic patients with sero-resistance. Foxp3, forkhead box P3.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Pre-treatment lymphocyte subpopulations profile of breast cancer and pathological response to neoadjuvant chemotherapy. A) representative digital images (100x) of ductal invasive carcinoma of the breast showing CD3, CD4, CD8, CD20, CD68 and Foxp3 staining (scale bar, 100 mum). B) unsupervised hierarchical clustering analysis of pre-chemotherapy TIL subpopulations yielded three groups or immune clusters (arbitrarily named A, B and C); each column represents a patient and each row represents an immunohistochemical marker. C) pathologic complete response distribution according to pre-chemotherapy immune cluster group. D) differential distribution of lymphocyte populations (CD3, CD4, CD8, CD20, Foxp3, CD68) according to pathological response to neoadjuvant chemotherapy; differences were statistically significant for CD3, CD4 and CD20 and non significant for CD8, Foxp3 and CD68. Statistical analysis: Mann-Whitney U-test. *, P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 Post-chemotherapy immune cell subpopulation profile and breast cancer prognosis. A) unsupervised hierarchical clustering analysis of post-chemotherapy immune cell populations generated two groups (named as Y and Z); each column represents a patient and each row represents an immunohistochemical marker. B) distribution of immune cell populations in post-chemotherapy cluster groups Y and Z; statistically significant higher infiltration was shown in cluster Y for all populations (CD3, CD4, CD8, CD20, Foxp3, CD68), Mann-Whitney U-test. C) Kaplan-Meier curves showed a worse disease-free survival for patients with tumors belonging to post-chemotherapy immune cluster Y ( P = 0.01). D) disease free survival curves according to post-treatment CD68 infiltration in residual tumor ( P = 0.055). E) Kaplan-Meier disease free survival curves according to level of post-treatment CD3 infiltration in residual tumor, showing an increasingly worse prognosis as CD3 infiltration increases ( P = 0.038). Hazard ratios (HR) and 95%CI calculated according to Cox proportional hazard regression models.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Phenotypic analysis of circulating regulatory T cells (Treg). A) Isolated PBMC were analyzed directly ex-vivo by flow cytometry. In the lymphogate, CD3 + CD4 + cells were assessed for the proportions of CD25 + FoxP3 + and CD25 + CD127 - Treg cells. Expression of CD45RA was analyzed to phenotype naive (CD45RA + ) and memory (CD45RA - ) Treg. B-D) The proportions of circulating CD25 + FoxP3 + (B) and CD25 + CD127 - (C)Treg, and of naive Treg (D) before and after vitamin D 3 supplementation (week 0 and 12). Significance was assessed with the Wilcoxon signed ranks comparison test.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 Naive CD4 + T cells are converted to functional Tregs by tumor-infiltrating DCs and tumor conditioned medium (CM). (A-C) Naive CD4 + T cells from peripheral blood of patients with invasive breast carcinoma were co-cultured with or without autologous pDCs isolated from tumor (TI) or peripheral blood (PB) for 9 days in the presence or absence of 30% CM from autologous tumor slices or adjacent normal tissue slices. (A , B) Non-adherent cells from co-cultures were stained for CD3, CD4, CD25 and intracellular Foxp3, and analyzed by flow cytometry. Representative plots of gated CD3 + CD4 + cells (A) and quantification of percentage of Foxp3 + CD25 + cells among CD3 + CD4 + cells (B) are shown (mean +- SEM, n = 19; * P < 0.05, ** P < 0.01, *** P < 0.001 by Student's t -test). (C) Expression of Treg-associated genes, assessed by qRT-PCR normalized to GAPDH , in sorted CD4 + T cells, relative to expression in cultures without DCs or CM (mean +- SEM, n = 19; * P < 0.05, ** P < 0.01, *** P < 0.001 compared with naive CD4 + T cells cultured alone by Student's t -test). (D-G) Effect of naive CD4 + T cell-derived Tregs, obtained by co-culture with TI pDCs and tumor CM as above, on function of autologous tumor-specific CD8 + T cells. Tumor-specific CD8 + T cells were generated for each subject by stimulating autologous PB CD8 + T cells with autologous tumor lysate-pulsed autologous DCs. Tregs were recovered from co-cultures by magnetic sorting. (D) CFSE-labeled CD8 + T ce
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 In vivo knockdown of PITPNM3 in CD4 + T cells reverses immunosuppression and inhibits tumor progression in humanized mice. (A) Humanized mice bearing palpable MDA-MB-231 orthotopic xenografts were intraperitoneally injected daily for 14 days with PBS, 1 nmol CD4-aptamer-control siRNA (AsiC-con) or CD4-aptamer-siRNA targeting PITPNM3 (sequence in A , AsiC-PI) to assess the role of PITPNM3 in TI Tregs, and other T cells and tumor control. Experimental schematic is provided in Supplementary information, Figure S9A . (B) Representative immunoblots showing selective knockdown of PITPNM3 protein in PB CD4 + T cells, but not tumor xenografts ( n = 3). (C) PITPNM3 knockdown did not affect the distribution of human CD45 + hematopoietic cells, CD4 + and CD8 + T cells, and CD14 + monocytes in the peripheral blood of humanized mice. Representative flow plots are shown ( n = 3). (D , E) Effect of PITPNM3 knockdown on TI naive CD4 + , Tregs and CD8 + T cell numbers, and apoptosis by TUNEL assay in xenografts. D shows representative immunofluorescence microscopy images. Top row indicates CD4 + naive T cells by arrows; the second row indicates CD4 + CD45RO + Foxp3 - CD4 + memory T cells (yellow arrows) and Foxp3 + Tregs (white arrows). Scale bar, 50 mum. E shows number of cells of each subtype/high power field in eight mice ( ** P < 0.01, *** P < 0.001 compared to PBS group by Student's t -test). (F) Flow cytometry analysis of gated human CD3 + CD4 + cells isolated from xenogra